GLPG Galapagos NV

102.02
-1.66  -2%
Previous Close 103.68
Open 104.09
Price To Book 4.11
Market Cap 5556562250
Shares 54,465,421
Volume 145,112
Short Ratio
Av. Daily Volume 99,586

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data lower than expectations released June 28, 2018.
GLPG2737 - PELICAN
Adult CF patients who are homozygous for the Class II F508del mutation
Phase 2 trial initiation announced July 5, 2017.
Filgotinib
Non-infectious uveitis
Phase 2 initiation announced June 26, 2018.
GLPG1972
Osteoarthritis
Phase 2 data due 2Q 2019.
Filgotinib and GS-9876
Cutaneous lupus erythematosus (CLE)
Phase 3 initiated August 2016
Filgotinib - FINCH 4
Rheumatoid arthritis (RA)
Phase 3 data due 1Q 2019.
Filgotinib - FINCH 3
Rheumatoid arthritis (RA)
Phase 3 data released September 11, 2018. Endpoints met.
Filgotinib - FINCH 2
Rheumatoid arthritis (RA)
Phase 2 data released September 6, 2018. Primary endpoint met.
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 2 data released May 30, 2018 - primary endpoint met.
Filgotinib - EQUATOR
Psoriatic arthritis
Phase 2a postive top-line data released November 20, 2017.
GLPG2222 - ALBATROSS
Cystic fibrosis (CF)
Phase 2 top-line data released December 20, 2016.
GLPG1837
Cystic Fibrosis
Phase 3 trial initiation announced December 17, 2018.
ISABELA - GLPG1690
Idiopathic pulmonary fibrosis
Phase 3 enrollment to be completed 4Q 2018.
Filgotinib - SELECTION
Ulcerative colitis
Phase 3 initiated November 2016. Enrollment to be completed 2H 2019.
Filgotinib - DIVERSITY
Crohn’s disease
Phase 3 data due 1Q 2019.
Filgotinib - FINCH 1
Rheumatoid arthritis (RA)
Phase 1b data released October 24, 2018 noted drug was well tolerated. Safety data due 1Q 2019.
GLPG 2451+2222+2737 - FALCON open label
Cystic fibrosis - homozygous F508del patients
Phase 2 trial initiation announced May 1, 2018. Completion due 2H 2019.
MOR106
Atopic dermatitis
Phase 2 initiation announced October 31, 2018.
GLPG1205 - PINTA
Idiopathic pulmonary fibrosis (IPF)
Phase 2 initiation announced January 7, 2019.
GLPG1690 - NOVESA
Systemic sclerosis

Latest News

  1. Sands Capital reports 5.7% holding in Galapagos
  2. Galapagos starts first Phase 1 trial with Toledo compound
  3. Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis
  4. Fibrocor and Galapagos sign partnership in fibrosis
  5. AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions
  6. How Should Investors React To Galapagos NV’s (AMS:GLPG) CEO Pay?
  7. Galapagos to Present at 37th Annual J.P. Morgan Healthcare Conference
  8. Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF)
  9. Recent Analysis Shows Best Buy Co., News Corporation, Semtech, Achaogen, Infosys, and Galapagos NV Market Influences — Renewed Outlook, Key Drivers of Growth
  10. Galapagos' Osteoarthritis Candidate Gets Fast Track Status
  11. Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis
  12. 5 Biotech Stocks to Scoop Up for Big Dividends
  13. Transparency notification
  14. Galapagos increases share capital through warrant exercises
  15. Vertex (VRTX) Gets Positive CHMP Opinion for Orkambi in Kids
  16. Why Galapagos (GLPG) Might Surprise This Earnings Season
  17. Galapagos reports initiation of PINTA Phase 2 trial with GLPG1205 in patients with Idiopathic Pulmonary Fibrosis (IPF)
  18. Factors of Influence in 2018, Key Indicators and Opportunity within ICON, Robert Half International, CenterPoint Energy, Galapagos NV, Canadian Pacific Railway, and Mobile Mini — New Research Emphasizes Economic Growth
  19. All You Need To Know About Galapagos NV’s (AMS:GLPG) Financial Health
  20. AbbVie to Assume Full Development and Commercial Control of Cystic Fibrosis Research Program